Dino Di Carlo,
Armond and Elena Hairapetian Chair in Engineering and Medicine, Professor and Vice Chair of Bioengineering,
University of California-Los Angeles
Dino Di Carlo received his B.S. in Bioengineering from the University of California, Berkeley in 2002 and received a Ph.D. in Bioengineering from the University of California, Berkeley and San Francisco in 2006. From 2006-2008 he conducted postdoctoral studies in the Center for Engineering in Medicine at Harvard Medical School. He has been on the faculty in the Department of Bioengineering at UCLA since 2008 and now as Professor of Bioengineering and Mechanical Engineering serves as the Vice Chair of the Department and as the director of the Cancer Nanotechnology Program in the Jonsson Comprehensive Cancer Center. His research pioneered the use of inertial fluid dynamic effects for the control, separation, and analysis of cells in microfluidic devices. His recent work extends into numerous other fields of biomedicine and biotechnology including directed evolution, cell analysis for rapid diagnostics, new amplified molecular assays, next generation biomaterials, and phenotypic drug screening. He has also been a leader in technology entrepreneurship: He co-founded and currently serves on the board of directors of five companies that are commercializing UCLA intellectual property developed in his lab (CytoVale, Vortex Biosciences, Tempo Therapeutics, Forcyte Biotechnologies and Ferrologix). Among other honors he received the Presidential Early Career Award for Scientists and Engineers (PECASE) and was elected a Fellow of the American Institute for Medical and Biological Engineering in 2016, was elected a Fellow of the Royal Society of Chemistry (FRSC) in 2014, was awarded the National Science Foundation (NSF) Faculty Early Career Development award and the U.S. Office of Naval Research (ONR) Young Investigator Award, the Packard Fellowship and Defense Advanced Research Projects Agency (DARPA) Young Faculty Award, and received the National Institutes of Health (NIH) Director’s New Innovator Award and Coulter Translational Research Award.
Lab on a Particle Technology to Unlock Antibody and Cell Therapy Discovery
Thursday, 6 October 2022 at 14:00
Add to Calendar ▼2022-10-06 14:00:002022-10-06 15:00:00Europe/LondonLab on a Particle Technology to Unlock Antibody and Cell Therapy DiscoveryLab-on-a-Chip and Microfluidics Asia 2022 in Tokyo, JapanTokyo, JapanSELECTBIOenquiries@selectbiosciences.com
We have developed 3D-shaped hydrogel microparticle platforms to capture cells, as well as isolate and label their secretions. These “lab on a particle” systems enable sorting cells based on secreted products for the discovery of antibodies, the development of cell lines producing recombinant products, and the selection of functional cells for cell therapies. Each cell and its secreted products can be analyzed using widely available flow cytometers operating at up to a 1000 cells per second. I will discuss our latest results in sorting antigen-specific T cells and mesenchymal stem cells based on secreted cytokines, extracellular vesicles, and growth factors. Cells sorted based on these properties are intact, can regrow, and maintain the selected function over multiple population doublings, enabling cell therapy discovery and manufacturing workflows.
Add to Calendar ▼2022-10-06 00:00:002022-10-07 00:00:00Europe/LondonLab-on-a-Chip and Microfluidics Asia 2022Lab-on-a-Chip and Microfluidics Asia 2022 in Tokyo, JapanTokyo, JapanSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2022-10-06 14:00:002022-10-06 15:00:00Europe/LondonLab on a Particle Technology to Unlock Antibody and Cell Therapy DiscoveryLab-on-a-Chip and Microfluidics Asia 2022 in Tokyo, JapanTokyo, JapanSELECTBIOenquiries@selectbiosciences.com
